Company Overview and News
Eden Innovations Ltd (ASX:EDE) shares traded as high as 7.8 cents today representing a 23.8% increase on yesterday’s closing price of 6.3 cents.
Eden Innovations (ASX:EDE) has secured a second order for over US$90,000 of EdenCrete® which has been delivered to a Texas based pre-stressed concrete manufacturer for use in bridge beams.
Eden Innovation Ltd (ASX:EDE) will have its concrete additive used when repairing all state funded, full depth concrete slab replacement projects on highways in the U.S. state of Georgia during FY2018.
UNITED STATES OF AMERICA before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release No. 75523 / July 27, 2015 Admin. Proc. File No. 3-16522 In the Matter of EDEN ENERGY CORP. AND FIFTH SEASON INTERNATIONAL, INC. NOTICE THAT INITIAL DECISION HAS BECOME FINAL The time for filing a petition for review of the initial decision in this proceeding has expired.
Eden Energy today announced plans to raise a further $15 million to support the commercial roll-out of its innovative concrete additive product, having tapped investors for $10.3 million in May this year.
Eden Energy Ltd (ASX:EDE) has been granted a trading halt by the ASX this morning, pending details of a capital raising. The halt will remain in place until the opening of trade on Thursday 15th September 2016, or earlier if an announcement was made to the market.
Tasman Resources Ltd (ASX:TAS) has entered a trading halt, pending details from Eden Energy Ltd (ASX:EDE) on a capital raising. Tasman is the major shareholder in Eden. The halt will remain in place until the opening of trade on Thursday 15th September 2016, or earlier if an announcement was made to the market.
Eden Energy Ltd’s (ASX:EDE) share price has gained after a breakthrough with the Georgia Department of Transportation (GDOT) in the U.S. to use EdenCrete concrete additive for highway repair projects. GDOT is identifying several suitable upcoming, state funded highway slab replacement projects in which it proposes to specify in the request for tender, that EdenCrete be added to the concrete. These projects, if awarded, will be the first commercial projects involving the use of EdenCrete on U.
Eden Energy Ltd (ASX:EDE) has been granted a trading halt by the ASX, pending an update in relation to the EdenCreteTM project. The halt will remain in place until the opening of trade on Monday 29th August 2016, or earlier if an announcement is made to the market.
Tasman Resources Ltd (ASX:TAS) has followed Eden Energy Ltd (ASX:EDE) into a trading halt this morning, pending an update in relation to the EdenCreteTM project. Tasman is the major shareholder in Eden. The halt will remain in place until the opening of trade on Monday 29th August 2016, or earlier if an announcement is made to the market.
Research and Markets has announced the addition of the "Global Carbon Nanotube Market 2016-2020" report to their offering.
Dublin - Research and Markets has announced the addition of the "Global Light Emitting Diode Packaging Equipment Market 2016-2020" report to their offering.
Research and Markets has announced the addition of the "Global Big Pharma Partnering Terms and Agreements 2010-2016: Deal trends, players and financials" report to their offering.
When the storm clouds hit, you need a port in a storm. In shares, these are healthcare, industrial and utility stocks, able to tick along when economics and markets become entrenched in volatility.
The Directors of Infinity Energy are pleased to announce the audited results of the Company for the year ended 31 December 2015.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...